- Home
- PAYS vs XFOR Comparison
PAYS vs XFOR Comparison
Compare PAYS & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAYS | XFOR |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United States |
| Employees | N/A | 45 |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.7M | 377.3M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PAYS | XFOR |
|---|---|---|
| Price | $8.29 | $4.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $9.42 | $9.00 |
| AVG Volume (30 Days) | 591.7K | ★ 957.1K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.71 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $24,120,434.00 | N/A |
| Revenue This Year | $33.83 | N/A |
| Revenue Next Year | $14.89 | N/A |
| P/E Ratio | $95.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.08 | $1.35 |
| 52 Week High | $8.88 | $4.83 |
Technical Indicators
Market Signals| Indicator | PAYS | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 64.85 | 50.44 |
| Support Level | $5.01 | $3.50 |
| Resistance Level | N/A | $4.38 |
| Average True Range (ATR) | 0.42 | 0.26 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 82.93 | 25.62 |
Price Performance
Historical ComparisonAbout PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.